101
|
McPherson VA, Sharma N, Everingham S, Smith J, Zhu HH, Feng GS, Craig AWB. SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc epsilon RI-induced activation of Fyn and Erk pathways leading to TNF alpha release from bone marrow-derived mast cells. THE JOURNAL OF IMMUNOLOGY 2009; 183:4940-7. [PMID: 19786542 DOI: 10.4049/jimmunol.0900702] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Clustering of the high affinity IgE receptor (Fc(epsilon)RI) in mast cells leads to degranulation and production of numerous cytokines and lipid mediators that promote allergic inflammation. Initiation of FFc(epsilon)RI signaling involves rapid tyrosine phosphorylation of Fc(epsilon)RI and membrane-localized adaptor proteins that recruit additional SH2 domain-containing proteins that dynamically regulate downstream signaling. SH2 domain-containing phosphatase-2 (SHP2) is a protein-tyrosine phosphatase implicated in Fc(epsilon)RI signaling, but whose function is not well defined. In this study, using a mouse model allowing temporal shp2 inactivation in bone marrow-derived mast cells (BMMCs), we provide insights into SHP2 functions in the Fc(epsilon)RI pathway. Although no overt defects in Fc(epsilon)RI-induced tyrosine phosphorylation were observed in SHP2 knock-out (KO) BMMCs, several proteins including Lyn and Syk kinases displayed extended phosphorylation kinetics compared with wild-type BMMCs. SHP2 was dispensable for Fc(epsilon)RI-induced degranulation of BMMCs, but was required for maximal activation of Erk and Jnk mitogen-activated protein kinases. SHP2 KO BMMCs displayed several phenotypes associated with reduced Fyn activity, including elevated phosphorylation of the inhibitory pY531 site in Fyn, impaired signaling to Grb2-associated binder 2, Akt/PKB, and IkappaB kinase, and decreased TNF-alpha release compared with control cells. This is likely due to elevated Lyn activity in SHP2 KO BMMCs, and the ability of Lyn to antagonize Fyn activity. Overall, our study identifies SHP2 as a positive effector of Fc(epsilon)RI-induced activation of Fyn/Grb2-associated binder 2/Akt and Ras/Erk pathways leading to TNF-alpha release from mast cells.
Collapse
Affiliation(s)
- Victor A McPherson
- Department of Biochemistry, Queen's University, Kingston, Ontario, Canada
| | | | | | | | | | | | | |
Collapse
|
102
|
Wöhrle FU, Daly RJ, Brummer T. Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal 2009; 7:22. [PMID: 19737390 PMCID: PMC2747914 DOI: 10.1186/1478-811x-7-22] [Citation(s) in RCA: 128] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2009] [Accepted: 09/08/2009] [Indexed: 01/13/2023] Open
Abstract
Since their discovery a little more than a decade ago, the docking proteins of the Gab/DOS family have emerged as important signalling elements in metazoans. Gab/DOS proteins integrate and amplify signals from a wide variety of sources including growth factor, cytokine and antigen receptors as well as cell adhesion molecules. They also contribute to signal diversification by channelling the information from activated receptors into signalling pathways with distinct biological functions. Recent approaches in protein biochemistry and systems biology have revealed that Gab proteins are subject to complex regulation by feed-forward and feedback phosphorylation events as well as protein-protein interactions. Thus, Gab/DOS docking proteins are at the centre of entire signalling subsystems and fulfil an important if not essential role in many physiological processes. Furthermore, aberrant signalling by Gab proteins has been increasingly linked to human diseases from various forms of neoplasia to Alzheimer's disease. In this review, we provide a detailed overview of the structure, effector functions, regulation and evolution of the Gab/DOS family. We also summarize recent findings implicating Gab proteins, in particular the Gab2 isoform, in leukaemia, solid tumours and other human diseases.
Collapse
Affiliation(s)
- Franziska U Wöhrle
- Centre for Biological Systems Analysis (ZBSA), Albert-Ludwigs-University of Freiburg, Germany.
| | | | | |
Collapse
|
103
|
Grochowy G, Hermiston ML, Kuhny M, Weiss A, Huber M. Requirement for CD45 in fine-tuning mast cell responses mediated by different ligand–receptor systems. Cell Signal 2009; 21:1277-86. [DOI: 10.1016/j.cellsig.2009.03.018] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2008] [Revised: 03/03/2009] [Accepted: 03/10/2009] [Indexed: 01/09/2023]
|
104
|
Yamaki K, Yoshino S. Comparison of inhibitory activities of zinc oxide ultrafine and fine particulates on IgE-induced mast cell activation. Biometals 2009; 22:1031-40. [DOI: 10.1007/s10534-009-9254-z] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2009] [Accepted: 07/03/2009] [Indexed: 10/20/2022]
|
105
|
Bohnacker T, Marone R, Collmann E, Calvez R, Hirsch E, Wymann MP. PI3K Adaptor Subunits Define Coupling to Degranulation and Cell Motility by Distinct PtdIns(3,4,5)P3 Pools in Mast Cells. Sci Signal 2009; 2:ra27. [DOI: 10.1126/scisignal.2000259] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
106
|
Liang G, Bansal G, Xie Z, Druey KM. RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling. J Biol Chem 2009; 284:21719-27. [PMID: 19509421 DOI: 10.1074/jbc.m109.028407] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Aberrant activity of the phosphatidylinositol 3-kinase (PI3K) pathway supports growth of many tumors including those of breast, lung, and prostate. Resistance of breast cancer cells to targeted chemotherapies including tyrosine kinase inhibitors (TKI) has been linked to persistent PI3K activity, which may in part be due to increased membrane expression of epidermal growth factor (EGF) receptors (HER2 and HER3). Recently we found that proteins of the RGS (regulator of G protein signaling) family suppress PI3K activity downstream of the receptor by sequestering its p85alpha subunit from signaling complexes. Because a substantial percentage of breast tumors have RGS16 mutations and reduced RGS16 protein expression, we investigated the link between regulation of PI3K activity by RGS16 and breast cancer cell growth. RGS16 overexpression in MCF7 breast cancer cells inhibited EGF-induced proliferation and Akt phosphorylation, whereas shRNA-mediated extinction of RGS16 augmented cell growth and resistance to TKI treatment. Exposure to TKI also reduced RGS16 expression in MCF7 and BT474 cell lines. RGS16 bound the amino-terminal SH2 and inter-SH2 domains of p85alpha and inhibited its interaction with the EGF receptor-associated adapter protein Gab1. These results suggest that the loss of RGS16 in some breast tumors enhances PI3K signaling elicited by growth factors and thereby promotes proliferation and TKI evasion downstream of HER activation.
Collapse
Affiliation(s)
- Genqing Liang
- Molecular Signal Transduction Section, Laboratory of Allergic Diseases, NIAID, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | | | |
Collapse
|
107
|
Distinct Binding Modes of Two Epitopes in Gab2 that Interact with the SH3C Domain of Grb2. Structure 2009; 17:809-22. [DOI: 10.1016/j.str.2009.03.017] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2009] [Revised: 03/11/2009] [Accepted: 03/20/2009] [Indexed: 01/11/2023]
|
108
|
Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis? Clin Sci (Lond) 2009; 116:791-804. [PMID: 19397491 DOI: 10.1042/cs20080549] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Inflammation has a central role in the pathogenesis of atherosclerosis at various stages of the disease. Therefore it appears of great interest to develop novel and innovative drugs targeting inflammatory proteins for the treatment of atherosclerosis. The PI3K (phosphoinositide 3-kinase) family, which catalyses the phosphorylation of the 3-OH position of phosphoinositides and generates phospholipids, controls a wide variety of intracellular signalling pathways. Recent studies provide evidence for a crucial role of this family not only in immune function, such as inflammatory cell recruitment, and expression and activation of inflammatory mediators, but also in antigen-dependent responses making it an interesting target to modulate inflammatory processes. The present review will focus on the regulation of inflammation within the vasculature during atherogenesis. We will concentrate on the different functions played by each isoform of PI3K in immune cells which could be involved in this pathology, raising the possibility that inhibition of one or more PI3K isoforms may represent an effective approach in the treatment of atherosclerosis.
Collapse
|
109
|
Akimoto M, Mishra K, Lim KT, Tani N, Hisanaga SI, Katagiri T, Elson A, Mizuno K, Yakura H. Protein Tyrosine Phosphatase ε is a Negative Regulator of FcεRI-mediated Mast Cell Responses. Scand J Immunol 2009; 69:401-11. [DOI: 10.1111/j.1365-3083.2009.02235.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
110
|
Abstract
Mast cell mediator release represents a pivotal event in the initiation of inflammatory reactions associated with allergic disorders. These responses follow antigen-mediated aggregation of immunoglobulin E (IgE)-occupied high-affinity receptors for IgE (Fc epsilon RI) on the mast cell surface, a response which can be further enhanced following stem cell factor-induced ligation of the mast cell growth factor receptor KIT (CD117). Activation of tyrosine kinases is central to the ability of both Fc epsilon RI and KIT to transmit downstream signaling events required for the regulation of mast cell activation. Whereas KIT possesses inherent tyrosine kinase activity, Fc epsilon RI requires the recruitment of Src family tyrosine kinases and Syk to control the early receptor-proximal signaling events. The signaling pathways propagated by these tyrosine kinases can be further upregulated by the Tec kinase Bruton's tyrosine kinase and downregulated by the actions of the tyrosine Src homology 2 domain-containing phosphatase 1 (SHP-1) and SHP-2. In this review, we discuss the regulation and role of specific members of this tyrosine kinase network in KIT and Fc epsilon RI-mediated mast cell activation.
Collapse
Affiliation(s)
- Alasdair M Gilfillan
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-1930, USA
| | | |
Collapse
|
111
|
Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein. EMBO J 2009; 27:2305-16. [PMID: 19172738 DOI: 10.1038/emboj.2008.159] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Grb2-associated binder (Gab)2 functions downstream of a variety of receptor and cytoplasmic tyrosine kinases as a docking platform for specific signal transducers and performs important functions in both normal physiology and oncogenesis. Gab2 signalling is promoted by its association with specific receptors through the adaptor Grb2. However, the molecular mechanisms that attenuate Gab2 signals have remained unclear. We now demonstrate that growth factor-induced phosphorylation of Gab2 on two residues, S210 and T391, leads to recruitment of 14-3-3 proteins. Together, these events mediate negative-feedback regulation, as Gab2(S210A/T391A) exhibits sustained receptor association and signalling and promotes cell proliferation and transformation. Importantly, introduction of constitutive 14-3-3-binding sites into Gab2 renders it refractory to receptor activation, demonstrating that site-selective binding of 14-3-3 proteins is sufficient to terminate Gab2 signalling. Furthermore, this is associated with reduced binding of Grb2. This leads to a model where signal attenuation occurs because 14-3-3 promotes dissociation of Gab2 from Grb2, and thereby uncouples Gab2 from the receptor complex. This represents a novel regulatory mechanism with implications for diverse tyrosine kinase signalling systems.
Collapse
|
112
|
Maus M, Medgyesi D, Kövesdi D, Csuka D, Koncz G, Sármay G. Grb2 associated binder 2 couples B-cell receptor to cell survival. Cell Signal 2008; 21:220-7. [PMID: 18950707 DOI: 10.1016/j.cellsig.2008.10.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2008] [Revised: 09/22/2008] [Accepted: 10/08/2008] [Indexed: 10/21/2022]
Abstract
B-cell fate during maturation and the germinal center reaction is regulated through the strength and the duration of the B-cell receptor signal. Signaling pathways discriminating between apoptosis and survival in B cells are keys in understanding adaptive immunity. Gab2 is a member of the Gab/Dos adaptor protein family. It has been shown in several model systems that Gab/Dos family members may regulate both the anti-apoptotic PI3-K/Akt and the mitogenic Ras/MAPK pathways, still their role in B-cells have not been investigated in detail. Here we studied the role of Gab2 in B-cell receptor mediated signaling. We have shown that BCR crosslinking induces the marked phosphorylation of Gab2 through both Lyn and Syk kinases. Subsequently Gab2 recruits p85 regulatory subunit of PI3-K, and SHP-2. Our results revealed that Ig-alpha/Ig-beta, signal transducing unit of the B-cell receptor, may function as scaffold recruiting Gab2 to the signalosome. Overexpression of Gab2 in A20 cells demonstrated that Gab2 is a regulator of the PI3-K/Akt but not that of the Ras/MAPK pathway in B cells. Accordingly to the elevated Akt phosphorylation, overexpression of wild-type Gab2 in A20 cells suppressed Fas-mediated apoptosis, and enhanced BCR-mediated rescue from Fas-induced cell death. Although PH-domain has only a stabilizing effect on membrane recruitment of Gab2, it is indispensable in mediating its anti-apoptotic effect.
Collapse
Affiliation(s)
- Máté Maus
- Department of Immunology at Eötvös Loránd University, Pázmány Péter sétány. 1/c, Budapest, 1117, Hungary
| | | | | | | | | | | |
Collapse
|
113
|
Rodrigues MS, Reddy MM, Sattler M. Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications. Antioxid Redox Signal 2008; 10:1813-48. [PMID: 18593226 DOI: 10.1089/ars.2008.2071] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Neoplastic expansion of myeloid cells is associated with specific genetic changes that lead to chronic activation of signaling pathways, as well as altered metabolism. It has become increasingly evident that transformation relies on the interdependency of both events. Among the various genetic changes, the oncogenic BCR-ABL tyrosine kinase in patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) has been a focus of extensive research. Transformation by this oncogene is associated with elevated levels of intracellular reactive oxygen species (ROS). ROS have been implicated in processes that promote viability, cell growth, and regulation of other biological functions such as migration of cells or gene expression. Currently, the BCR-ABL inhibitor imatinib mesylate (Gleevec) is being used as a first-line therapy for the treatment of CML. However, BCR-ABL transformation is associated with genomic instability, and disease progression or resistance to imatinib can occur. Imatinib resistance is not known to cause or significantly alter signaling requirements in transformed cells. Elevated ROS are crucial for transformation, making them an ideal additional target for therapeutic intervention. The underlying mechanisms leading to elevated oxidative stress are reviewed, and signaling mechanisms that may serve as novel targeted approaches to overcome ROS-dependent cell growth are discussed.
Collapse
Affiliation(s)
- Margret S Rodrigues
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA
| | | | | |
Collapse
|
114
|
Ray P, Krishnamoorthy N, Ray A. Emerging functions of c-kit and its ligand stem cell factor in dendritic cells: regulators of T cell differentiation. Cell Cycle 2008; 7:2826-32. [PMID: 18787413 DOI: 10.4161/cc.7.18.6752] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
The receptor tyrosine kinase, c-kit, and its ligand, stem cell factor (SCF), function in a diverse range of biological functions. The role of c-kit in the maintenance and survival of hematopoietic stem cells and of mast cells is well recognized. c-kit also plays an important role in melanogenesis, erythropoiesis and spermatogenesis. Recent work from our laboratory highlights an important role of c-kit in the regulation of expression of two molecules in dendritic cells (DCs), interleukin-6 (IL-6) and Jagged-2 (a ligand of Notch), which are known to regulate T helper cell differentiation. Our study shows that induction of c-kit expression and its signaling in DCs promotes Th2 and Th17 responses but not Th1 response. c-kit inhibition by imatinib mesylate (Gleevec) in DCs was previously shown to promote natural killer cell activation which may be due to dampening of IL-6 production by the DCs. Since dysregulation of c-kit function has been associated with various disease states including cancer, in this perspective we have focused on known and novel functions of c-kit to include molecules such as IL-6 and Notch that were not previously recognized to be within the purview of c-kit biology. We have also reviewed the differential expression pattern of SCF and c-kit on various cell types and its variation during development or pathology. The recognition of previously unappreciated roles for c-kit will provide better insights into its function within and beyond the immune system and pave the way for developing better therapeutic strategies.
Collapse
Affiliation(s)
- Prabir Ray
- Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
| | | | | |
Collapse
|
115
|
Peterfy H, Toth G, Pecht I, Erdei A. C3a-derived peptide binds to the type I Fc R and inhibits proximal-coupling signal processes and cytokine secretion by mast cells. Int Immunol 2008; 20:1239-45. [DOI: 10.1093/intimm/dxn083] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
116
|
Nunomura S, Yoshimaru T, Ra C. Na-Tosyl-Phe chloromethyl ketone prevents granule movement and mast cell synergistic degranulation elicited by costimulation of antigen and adenosine. Life Sci 2008; 83:242-9. [PMID: 18634805 DOI: 10.1016/j.lfs.2008.06.015] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2008] [Revised: 05/08/2008] [Accepted: 06/07/2008] [Indexed: 12/11/2022]
Abstract
Adenosine has been shown to enhance mast cell degranulation when added together with an antigen. Such augmentation of mast cell activation is relevant to exacerbation of allergic asthma symptoms. Na-Tosyl-Phe chloromethyl ketone (TPCK) is a chymotrypsine-like chymase inhibitor, which has anti-inflammatory properties. In this study, we investigated the effects of TPCK on mast cell synergistic degranulation induced by antigen and adenosine. Here, we report that TPCK almost completely suppressed enhanced degranulation by inhibiting granule movement. Consistent with this, intraperitoneal administration of TPCK resulted in significant amelioration of passive cutaneous anaphylaxis in mice. Furthermore, we demonstrated that TPCK completely inhibited Thr308 phosphorylation of protein kinase B in mast cells stimulated with antigen and adenosine. These results provide a novel action of TPCK for the prevention of mast cell degranulation induced by antigen and adenosine.
Collapse
Affiliation(s)
- Satoshi Nunomura
- Division of Molecular Cell Immunology and Allergology, Nihon University Graduate School of Medical Science, Japan
| | | | | |
Collapse
|
117
|
Pyarajan S, Matejovic G, Pratt JC, Baksh S, Burakoff SJ. Interleukin-3 (IL-3)-induced c-fos activation is modulated by Gab2-calcineurin interaction. J Biol Chem 2008; 283:23505-9. [PMID: 18586679 DOI: 10.1074/jbc.c800087200] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Interleukin-3 (IL-3) regulates cell growth by affecting various processes such as cell death, survival, and proliferation. Cues from the external environment are sensed by surface receptors, and complex signaling mechanisms arise within the cells, leading to specific functional outcomes. In this study, we demonstrate that the cytokine IL-3 induces the activation of the Ca(2+)-dependent phosphatase, calcineurin (Cn). Furthermore Cn dephosphorylates Gab2, resulting in c-fos activation and cell proliferation. We also report that there is a direct interaction between Cn and Gab2 upon IL-3 stimulation, and Akt can regulate this interaction.
Collapse
Affiliation(s)
- Saiju Pyarajan
- Cancer Institute, NYU School of Medicine, New York University, New York, NY 10016, USA.
| | | | | | | | | |
Collapse
|
118
|
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood 2008; 112:2463-73. [PMID: 18579792 DOI: 10.1182/blood-2007-09-115477] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
The D816V-mutated variant of Kit triggers multiple signaling pathways and is considered essential for malignant transformation in mast cell (MC) neoplasms. We here describe that constitutive activation of the Stat5-PI3K-Akt-cascade controls neoplastic MC development. Retrovirally transduced active Stat5 (cS5(F)) was found to trigger PI3K and Akt activation, and to transform murine bone marrow progenitors into tissue-infiltrating MCs. Primary neoplastic Kit D816V(+) MCs in patients with mastocytosis also displayed activated Stat5, which was found to localize to the cytoplasm and to form a signaling complex with PI3K, with consecutive Akt activation. Finally, the knock-down of either Stat5 or Akt activity resulted in growth inhibition of neoplastic Kit D816V(+) MCs. These data suggest that a downstream Stat5-PI3K-Akt signaling cascade is essential for Kit D816V-mediated growth and survival of neoplastic MCs.
Collapse
|
119
|
Palmisano M, Grafone T, Renzulli M, Ottaviani E, Testoni N, Paolini S, Papayannidis C, Baccarani M, Martinelli G. Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. ACTA ACUST UNITED AC 2008; 13:1-12. [PMID: 18534059 DOI: 10.1179/102453308x315753] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Acute myeloid leukemia (AML) remains the most common form of leukemia and the most common cause of leukemia death. Although conventional chemotherapy can cure between 25 and 45% of AML patients, the majority of patients die after relapse or of complications associated with treatment. Thus, more specific and less toxic treatments for AML patients are needed, especially for elderly patients. An indispensable prerequisite to investigate tailored approaches for AML is the recent progress in the understanding the molecular features that distinguish leukemia progenitors from normal hematopoietic counterparts and the identification of a variety of dysregulated molecular pathways. This in turn would allow the identification of tumor-specific characteristics that provide a rational basis for the development of more tailored, and hence potentially more effective and less toxic, therapeutic approaches. In this review, we describe some of the signaling pathways that are aberrantly regulated in AML, with a specific focus on their pathogenetic and therapeutic significance, and we examine some recent therapies directed against these targets, used in clinical trial for relapsed patients or unfit for conventional chemotherapy.
Collapse
Affiliation(s)
- Michela Palmisano
- Institute of Hematology and Medical Oncology L. e A. Seràgnoli, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
120
|
Kim MS, Kuehn HS, Metcalfe DD, Gilfillan AM. Activation and function of the mTORC1 pathway in mast cells. THE JOURNAL OF IMMUNOLOGY 2008; 180:4586-95. [PMID: 18354181 DOI: 10.4049/jimmunol.180.7.4586] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Little is known about the signals downstream of PI3K which regulate mast cell homeostasis and function following FcepsilonRI aggregation and Kit ligation. In this study, we investigated the role of the mammalian target of rapamycin complex 1 (mTORC1) pathway in these responses. In human and mouse mast cells, stimulation via FcepsilonRI or Kit resulted in a marked PI3K-dependent activation of the mTORC1 pathway, as revealed by the wortmannin-sensitive sequential phosphorylation of tuberin, mTOR, p70S6 kinase (p70S6K), and 4E-BP1. In contrast, in human tumor mast cells, the mTORC1 pathway was constitutively activated and this was associated with markedly elevated levels of mTORC1 pathway components. Rapamycin, a specific inhibitor of mTORC1, selectively and completely blocked the FcepsilonRI- and Kit-induced mTORC1-dependent p70S6K phosphorylation and partially blocked the 4E-BP1 phosphorylation. In parallel, although rapamycin had no effect on FcepsilonRI-mediated degranulation or Kit-mediated cell adhesion, it inhibited cytokine production, and kit-mediated chemotaxis and cell survival. Furthermore, Rapamycin also blocked the constitutive activation of the mTORC1 pathway and inhibited cell survival of tumor mast cells. These data provide evidence that mTORC1 is a point of divergency for the PI3K-regulated downstream events of FcepsilonRI and Kit for the selective regulation of mast cell functions. Specifically, the mTORC1 pathway may play a critical role in normal and dysregulated control of mast cell homeostasis.
Collapse
Affiliation(s)
- Mi-Sun Kim
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
| | | | | | | |
Collapse
|
121
|
Sivalenka RR, Sinha M, Jessberger R. SWAP-70 regulates mast cell FcepsilonRI-mediated signaling and anaphylaxis. Eur J Immunol 2008; 38:841-54. [PMID: 18236401 DOI: 10.1002/eji.200737597] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Mast cells, perhaps best known by their ability to trigger allergic reactions after stimulation through the FcepsilonRI, express the unusual phosphatidylinositol 3-kinase (PI3K)-dependent, Rac-binding protein SWAP-70. Here, we show that the IgE-mediated passive cutaneous and the systemic anaphylactic responses are strongly reduced in SWAP-70(-/-) mice. Cultured SWAP-70(-/-) immature bone marrow mast cells (BMMC) are also impaired in FcepsilonRI-mediated degranulation, which can be restored by expression of exogenous wild-type SWAP-70, but less so if a phosphatidylinositol trisphosphate (PIP(3)) binding mutant is expressed. SWAP-70 itself supports inositol-3-phosphate and PIP(3) production, the latter indicating a potential feedback from SWAP-70 towards PI3K. FcepsilonRI-stimulated transcription and release of cytokines is controlled by SWAP-70. Key FcepsilonRI signal transduction events like activation of LAT by phosphorylation, activation of Akt/PKB and of p38 MAP kinase are reduced in SWAP-70(-/-) BMMC, but ERK is strongly hyperactivated. Some requirements for SWAP-70 were apparent only under limited-strength signaling conditions. We suggest that SWAP-70 defines a new element of efficient mast cell activation upon FcepsilonRI signaling, important for the control of mast cell-dependent anaphylaxis.
Collapse
Affiliation(s)
- Raja R Sivalenka
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY, USA
| | | | | |
Collapse
|
122
|
A current understanding of Fc epsilon RI-dependent mast cell activation. Curr Allergy Asthma Rep 2008; 8:14-20. [PMID: 18377769 DOI: 10.1007/s11882-008-0004-z] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Mast cell activation via the high-affinity immunoglobulin (Ig) E receptor Fc epsilon RI is a topic of extensive investigation with therapeutic potential in allergic disease. The protein tyrosine kinases Fyn, Lyn, and Syk are intimately linked with the early events initiated by allergen-mediated aggregation of IgE-occupied Fc epsilon RI. Fyn and Lyn initiate signaling events that are organized by adaptor molecules, which compartmentalize and coordinate the activity of activated protein and lipid kinases and phospholipases to generate lipid products essential for signal amplification and mast cell function. Fyn and Lyn counter-regulate phosphatidylinositol 3-OH kinase (PI3K), controlling the produced amount of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a key regulator of mast cell degranulation. Fyn and Lyn also activate sphingosine kinases (SphK), which generate sphingosine-1-phosphate (S1P), thus contributing to mast cell chemotaxis and degranulation. Here, we summarize the current knowledge and future challenges and directions.
Collapse
|
123
|
Ali K, Camps M, Pearce WP, Ji H, Rückle T, Kuehn N, Pasquali C, Chabert C, Rommel C, Vanhaesebroeck B. Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. THE JOURNAL OF IMMUNOLOGY 2008; 180:2538-44. [PMID: 18250464 DOI: 10.4049/jimmunol.180.4.2538] [Citation(s) in RCA: 98] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The leukocyte-enriched p110gamma and p110delta isoforms of PI3K have been shown to control in vitro degranulation of mast cells induced by cross-linking of the high affinity receptor of IgE (FcepsilonRI). However, the relative contribution of these PI3K isoforms in IgE-dependent allergic responses in vivo is controversial. A side-by-side comparative analysis of the role of p110gamma and p110delta in mast cell function, using genetic approaches and newly developed isoform-selective pharmacologic inhibitors, confirms that both PI3K isoforms play an important role in FcepsilonRI-activated mast cell degranulation in vitro. In vivo, however, only p110delta was found to be required for optimal IgE/Ag-dependent hypersensitivity responses in mice. These observations identify p110delta as a key therapeutic target among PI3K isoforms for allergy- and mast cell-related diseases.
Collapse
Affiliation(s)
- Khaled Ali
- Centre for Cell Signalling, Institute of Cancer, Queen Mary University of London, Sir John Vane Research Centre, Charterhouse Square, London, United Kingdom
| | | | | | | | | | | | | | | | | | | |
Collapse
|
124
|
Mast cell transcriptional networks. Blood Cells Mol Dis 2008; 41:82-90. [PMID: 18406636 DOI: 10.1016/j.bcmd.2008.02.005] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2008] [Accepted: 02/06/2008] [Indexed: 11/20/2022]
Abstract
Unregulated activation of mast cells can contribute to the pathogenesis of inflammatory and allergic diseases, including asthma, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Absence of mast cells in animal models can lead to impairment in the innate immune response to parasites and bacterial infections. Aberrant clonal accumulation and proliferation of mast cells can result in a variety of diseases ranging from benign cutaneous mastocytosis to systemic mastocytosis or mast cell leukemia. Understanding mast cell differentiation provides important insights into mechanisms of lineage selection during hematopoiesis and can provide targets for new drug development to treat mast cell disorders. In this review, we discuss controversies related to development, sites of origin, and the transcriptional program of mast cells.
Collapse
|
125
|
Olivera A. Unraveling the complexities of sphingosine-1-phosphate function: the mast cell model. Prostaglandins Other Lipid Mediat 2008; 86:1-11. [PMID: 18403224 DOI: 10.1016/j.prostaglandins.2008.02.005] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2008] [Accepted: 02/26/2008] [Indexed: 11/16/2022]
Abstract
Sphingosine-1-phosphate (S1P) is a lipid mediator involved in diverse biological processes, from vascular and neural development to the regulation of lymphocyte trafficking. Many of its functions are regulated by five widely expressed S1P G-protein-coupled receptors (S1P(1-5)). S1P is produced mostly intracellularly, thus, much of its potential as an autocrine and paracrine mediator depends on how, when, and where it is generated or secreted out of the cells. However, S1P can also have intracellular activity independent of its receptors, adding to the complexity of S1P function. The mast cell, a major effector cell during an allergic response, has proven instrumental towards understanding the complex regulation and function of S1P. Antigen (Ag) engagement of the IgE receptor in mast cells stimulates sphingosine kinases, which generate S1P and are involved in the activation of calcium fluxes critical for mast cell responses. In addition, mast cells secrete considerable amounts of S1P upon activation, thus affecting the surrounding tissues and recruiting inflammatory cells. Export of S1P is also involved in the autocrine transactivation of S1P receptors present in mast cells. The in vivo response of mast cells, however, is not strictly dependent on their ability to generate S1P, but they are also affected by changes in S1P in the environment previous to Ag challenge. This review will discuss the recent advances towards understanding the intricacies of S1P generation, secretion and regulation in mast cells. In addition, how S1P receptors are activated and their involvement in mast cell functions will also be covered, including new insights on the role of S1P in the mast cell-mediated allergic response of systemic anaphylaxis.
Collapse
Affiliation(s)
- Ana Olivera
- Laboratory of Immune Cell Signaling, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9 Memorial Dr, Bldg 9, room# 1W122, Bethesda, MD 20892, USA.
| |
Collapse
|
126
|
Huang F, Yamaki K, Tong X, Fu L, Zhang R, Cai Y, Yanagisawa R, Inoue KI, Takano H, Yoshino S. Inhibition of the antigen-induced activation of RBL-2H3 cells by sinomenine. Int Immunopharmacol 2008; 8:502-7. [DOI: 10.1016/j.intimp.2007.12.009] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2007] [Revised: 12/13/2007] [Accepted: 12/18/2007] [Indexed: 10/22/2022]
|
127
|
Kuehn HS, Beaven MA, Ma HT, Kim MS, Metcalfe DD, Gilfillan AM. Synergistic activation of phospholipases Cgamma and Cbeta: a novel mechanism for PI3K-independent enhancement of FcepsilonRI-induced mast cell mediator release. Cell Signal 2008; 20:625-36. [PMID: 18207701 DOI: 10.1016/j.cellsig.2007.11.016] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2007] [Revised: 11/19/2007] [Accepted: 11/20/2007] [Indexed: 10/24/2022]
Abstract
Antigen/IgE-mediated mast cell activation via FcvarepsilonRI can be markedly enhanced by the activation of other receptors expressed on mast cells and these receptors may thus contribute to the allergic response in vivo. One such receptor family is the G protein-coupled receptors (GPCRs). Although the signaling cascade linking FcvarepsilonRI aggregation to mast cell activation has been extensively investigated, the mechanisms by which GPCRs amplify this response are relatively unknown. To investigate this, we utilized prostaglandin (PG)E2 based on initial studies demonstrating its greater ability to augment antigen-mediated degranulation in mouse mast cells than other GPCR agonists examined. This enhancement, and the ability of PGE2 to amplify antigen-induced calcium mobilization, was independent of phosphoinositide 3-kinase but was linked to a pertussis toxin-sensitive synergistic translocation to the membrane of phospholipase (PL)Cgamma and PLCbeta and to an enhancement of PLCgamma phosphorylation. This "trans-synergistic" activation of PLCbeta and gamma, in turn, enhanced production of inositol 1,4,5-trisphosphate, store-operated calcium entry, and activation of protein kinase C (PKC) (alpha and beta). These responses were critical for the promotion of degranulation. This is the first report of synergistic activation between PLCgamma and PLCbeta that permits reinforcement of signals for degranulation in mast cells.
Collapse
Affiliation(s)
- Hye Sun Kuehn
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive MSC 1881, Bethesda, MD 20892-1881, USA
| | | | | | | | | | | |
Collapse
|
128
|
Rivera J, Fierro NA, Olivera A, Suzuki R. New insights on mast cell activation via the high affinity receptor for IgE. Adv Immunol 2008; 98:85-120. [PMID: 18772004 PMCID: PMC2761150 DOI: 10.1016/s0065-2776(08)00403-3] [Citation(s) in RCA: 162] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Mast cells are innate immune cells that function as regulatory or effector cells and serve to amplify adaptive immunity. In adaptive immunity these cells function primarily through cell surface Fc receptors that bind immunoglobulin antibodies. The dysregulation of their adaptive role makes them central players in allergy and asthma. Upon encountering an allergen (antigen), which is recognized by immunoglobulin E (IgE) antibodies bound to the high affinity IgE receptor (FcepsilonRI) expressed on their cell surface, mast cells secrete both preformed and newly synthesized mediators of the allergic response. Blocking of these responses is an objective in therapeutic intervention of allergic diseases. Thus, understanding the mechanisms by which antigens elicit mast cell activation (via FcepsilonRI) holds promise toward identifying therapeutic targets. Here we review the most recent advances in understanding antigen-dependent mast cell activation. Specifically, we focus on the requirements for FcepsilonRI activation, the regulation of calcium responses, co-stimulatory signals in FcepsilonRI-mediated mast cell activation and function, and how genetics influences mast cell signaling and responses. These recent discoveries open new avenues of investigation with therapeutic potential.
Collapse
Affiliation(s)
- Juan Rivera
- Laboratory of Immune Cell Signaling, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | | | | | | |
Collapse
|
129
|
Dráberová L, Shaik GM, Volná P, Heneberg P, Tůmová M, Lebduska P, Korb J, Dráber P. Regulation of Ca2+ signaling in mast cells by tyrosine-phosphorylated and unphosphorylated non-T cell activation linker. THE JOURNAL OF IMMUNOLOGY 2007; 179:5169-80. [PMID: 17911602 DOI: 10.4049/jimmunol.179.8.5169] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Engagement of the FcepsilonRI in mast cells and basophils leads to a rapid tyrosine phosphorylation of the transmembrane adaptors LAT (linker for activation of T cells) and NTAL (non-T cell activation linker, also called LAB or LAT2). NTAL regulates activation of mast cells by a mechanism, which is incompletely understood. Here we report properties of rat basophilic leukemia cells with enhanced or reduced NTAL expression. Overexpression of NTAL led to changes in cell morphology, enhanced formation of actin filaments and inhibition of the FcepsilonRI-induced tyrosine phosphorylation of the FcepsilonRI subunits, Syk kinase and LAT and all downstream activation events, including calcium and secretory responses. In contrast, reduced expression of NTAL had little effect on early FcepsilonRI-induced signaling events but inhibited calcium mobilization and secretory response. Calcium response was also repressed in Ag-activated cells defective in Grb2, a major target of phosphorylated NTAL. Unexpectedly, in cells stimulated with thapsigargin, an inhibitor of the endoplasmic reticulum Ca(2+) ATPase, the amount of cellular NTAL directly correlated with the uptake of extracellular calcium even though no enhanced tyrosine phosphorylation of NTAL was observed. The combined data indicate that NTAL regulates FcepsilonRI-mediated signaling at multiple steps and by different mechanisms. At early stages NTAL interferes with tyrosine phosphorylation of several substrates and formation of signaling assemblies, whereas at later stages it regulates the activity of store-operated calcium channels through a distinct mechanism independent of enhanced NTAL tyrosine phosphorylation.
Collapse
Affiliation(s)
- Lubica Dráberová
- Department of Signal Transduction, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | | | | | | | | | | | | | | |
Collapse
|
130
|
Abstract
Abnormalities of cytokine and growth factor signaling pathways are characteristic of all forms of leukemia: lymphoid and myeloid, acute and chronic. In normal hematopoietic cells, cytokines provide the stimulus for proliferation, survival, self-renewal, differentiation and functional activation. In leukemic cells, these pathways are usurped to subserve critical parts of the malignant program. In this review, our current knowledge of leukemic cell cytokine signaling will be summarized, and some speculations on the significance and implications of these insights will be advanced. A better understanding of aberrant cytokine signaling in leukemia should provide additional targets for the rational therapy of these diseases.
Collapse
Affiliation(s)
- R A Van Etten
- Molecular Oncology Research Institute and Division of Hematology/Oncology, Tufts-New England Medical Center, Boston, MA 02111, USA.
| |
Collapse
|
131
|
Suppression of immunoglobulin E-mediated allergic responses by regulator of G protein signaling 13. Nat Immunol 2007; 9:73-80. [PMID: 18026105 DOI: 10.1038/ni1533] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2007] [Accepted: 10/09/2007] [Indexed: 12/19/2022]
Abstract
Mast cells elicit allergic responses through degranulation and release of proinflammatory mediators after antigen crosslinking of the immunoglobulin E receptor FcepsilonRI. Proteins of the 'regulator of G protein signaling' (RGS) family negatively control signaling mediated by G protein-coupled receptors through GTPase-accelerating protein activity. Here we show that RGS13 inhibited allergic responses by physically interacting with the regulatory p85alpha subunit of phosphatidylinositol-3-OH kinase in mast cells and disrupting its association with an FcepsilonRI-activated scaffolding complex. Rgs13-/- mice had enhanced immunoglobulin E-mediated mast cell degranulation and anaphylaxis. Thus, RGS13 inhibits the assembly of immune receptor-induced signalosomes in mast cells. Abnormal RGS13 expression or function may contribute to disorders of amplified mast cell activity, such as idiopathic anaphylaxis.
Collapse
|
132
|
Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS 2007; 1784:159-85. [PMID: 17997386 DOI: 10.1016/j.bbapap.2007.10.003] [Citation(s) in RCA: 451] [Impact Index Per Article: 26.5] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Received: 08/15/2007] [Revised: 09/28/2007] [Accepted: 10/05/2007] [Indexed: 01/08/2023]
Abstract
Phosphoinositide 3-kinases (PI3K) orchestrate cell responses including mitogenic signaling, cell survival and growth, metabolic control, vesicular trafficking, degranulation, cytoskeletal rearrangement and migration. Deregulation of the PI3K pathway occurs by activating mutations in growth factor receptors or the PIK3CA locus coding for PI3Kalpha, by loss of function of the lipid phosphatase and tensin homolog deleted in chromosome ten (PTEN/MMAC/TEP1), by the up-regulation of protein kinase B (PKB/Akt), or the impairment of the tuberous sclerosis complex (TSC1/2). All these events are linked to growth and proliferation, and have thus prompted a significant interest in the pharmaceutical targeting of the PI3K pathway in cancer. Genetic targeting of PI3Kgamma (p110gamma) and PI3Kdelta (p110delta) in mice has underlined a central role of these PI3K isoforms in inflammation and allergy, as they modulate chemotaxis of leukocytes and degranulation in mast cells. Proof-of-concept molecules selective for PI3Kgamma have already successfully alleviated disease progress in murine models of rheumatoid arthritis and lupus erythematosus. As targeting PI3K moves forward to therapy of chronic, non-fatal disease, safety concerns for PI3K inhibitors increase. Many of the present inhibitor series interfere with target of rapamycin (TOR), DNA-dependent protein kinase (DNA-PK(cs)) and activity of the ataxia telangiectasia mutated gene product (ATM). Here we review the current disease-relevant knowledge for isoform-specific PI3K function in the above mentioned diseases, and review the progress of >400 recent patents covering pharmaceutical targeting of PI3K. Currently, several drugs targeting the PI3K pathway have entered clinical trials (phase I) for solid tumors and suppression of tissue damage after myocardial infarction (phases I,II).
Collapse
Affiliation(s)
- Romina Marone
- Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Mattenstrasse 28, CH-4058, Basel, Switzerland
| | | | | | | |
Collapse
|
133
|
Jensen BM, Beaven MA, Iwaki S, Metcalfe DD, Gilfillan AM. Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation. J Pharmacol Exp Ther 2007; 324:128-38. [PMID: 17925481 DOI: 10.1124/jpet.107.125237] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Although primarily required for the growth, differentiation, and survival of mast cells, Kit ligand (stem cell factor) is also required for optimal antigen-mediated mast cell activation. Therefore, concurrent inhibition of Kit- and FcepsilonRI-mediated signaling would be an attractive approach for targeting mast cell-driven allergic reactions. To explore this concept, we examined the effects of hypothemycin, a molecule that we identified as having such properties, in human and mouse mast cells. Hypothemycin blocked Kit activation and Kit-mediated mast cell adhesion in a similar manner to the well characterized Kit inhibitor imatinib mesylate (imatinib). In contrast to imatinib, however, hypothemycin also effectively inhibited FcepsilonRI-mediated degranulation and cytokine production in addition to the potentiation of these responses via Kit. The effect of hypothemycin on Kit-mediated responses could be explained by its inhibition of Kit kinase activity, whereas the inhibitory effects on FcepsilonRI-dependent signaling were at the level of Btk activation. Because hypothemycin also significantly reduced the mouse passive cutaneous anaphylaxis response in vivo, these data provide proof of principle for a coordinated approach for the suppression of mast cell activation and provide a rationale for the development of compounds with a similar therapeutic profile.
Collapse
Affiliation(s)
- Bettina M Jensen
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11C206, 10 Center Drive, MSC 1881, Bethesda, MD 20892-1881, USA
| | | | | | | | | |
Collapse
|
134
|
Nakaoka Y, Nishida K, Narimatsu M, Kamiya A, Minami T, Sawa H, Okawa K, Fujio Y, Koyama T, Maeda M, Sone M, Yamasaki S, Arai Y, Koh GY, Kodama T, Hirota H, Otsu K, Hirano T, Mochizuki N. Gab family proteins are essential for postnatal maintenance of cardiac function via neuregulin-1/ErbB signaling. J Clin Invest 2007; 117:1771-81. [PMID: 17571162 PMCID: PMC1888569 DOI: 10.1172/jci30651] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2006] [Accepted: 04/10/2007] [Indexed: 01/11/2023] Open
Abstract
Grb2-associated binder (Gab) family of scaffolding adaptor proteins coordinate signaling cascades downstream of growth factor and cytokine receptors. In the heart, among EGF family members, neuregulin-1beta (NRG-1beta, a paracrine factor produced from endothelium) induced remarkable tyrosine phosphorylation of Gab1 and Gab2 via erythroblastic leukemia viral oncogene (ErbB) receptors. We examined the role of Gab family proteins in NRG-1beta/ErbB-mediated signal in the heart by creating cardiomyocyte-specific Gab1/Gab2 double knockout mice (DKO mice). Although DKO mice were viable, they exhibited marked ventricular dilatation and reduced contractility with aging. DKO mice showed high mortality after birth because of heart failure. In addition, we noticed remarkable endocardial fibroelastosis and increase of abnormally dilated vessels in the ventricles of DKO mice. NRG-1beta induced activation of both ERK and AKT in the hearts of control mice but not in those of DKO mice. Using DNA microarray analysis, we found that stimulation with NRG-1beta upregulated expression of an endothelium-stabilizing factor, angiopoietin 1, in the hearts of control mice but not in those of DKO mice, which accounted for the pathological abnormalities in the DKO hearts. Taken together, our observations indicated that in the NRG-1beta/ErbB signaling, Gab1 and Gab2 of the myocardium are essential for both maintenance of myocardial function and stabilization of cardiac capillary and endocardial endothelium in the postnatal heart.
Collapse
Affiliation(s)
- Yoshikazu Nakaoka
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Keigo Nishida
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Masahiro Narimatsu
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Atsunori Kamiya
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Takashi Minami
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Hirofumi Sawa
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Katsuya Okawa
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Yasushi Fujio
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Tatsuya Koyama
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Makiko Maeda
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Manami Sone
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Satoru Yamasaki
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Yuji Arai
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Gou Young Koh
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Tatsuhiko Kodama
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Hisao Hirota
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Kinya Otsu
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Toshio Hirano
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Naoki Mochizuki
- Department of Structural Analysis, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology (RCAI), Yokohama, Japan.
Laboratory of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Dynamics, National Cardiovascular Center Research Institute, Osaka, Japan.
Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Department of Molecular Pathobiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Horizontal Medical Research Organization, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Evaluation of Medicines and Therapeutics, Osaka University Graduate School of Pharmaceutical Sciences, Osaka, Japan.
Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan.
Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
135
|
Oksvold MP, Dagger SA, Thien CBF, Langdon WY. The Cbl-b RING finger domain has a limited role in regulating inflammatory cytokine production by IgE-activated mast cells. Mol Immunol 2007; 45:925-36. [PMID: 17868870 DOI: 10.1016/j.molimm.2007.08.002] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2007] [Revised: 08/03/2007] [Accepted: 08/06/2007] [Indexed: 12/26/2022]
Abstract
The RING finger type E3 ubiquitin ligase, Cbl-b, is abundantly expressed in bone marrow-derived mast cells (BMMCs) and functions as a potent negative regulator of signalling responses from the high-affinity IgE receptor (FcvarepsilonRI). To determine the contribution of Cbl-b E3 ligase activity we generated knockin mice with a loss-of-function mutation in the RING finger domain. We find the mice to be healthy and, unlike equivalent c-Cbl RING finger mutant mice, produce homozygous offspring at the expected frequency. Comparative analyses of BMMCs from Cbl-b knockout and Cbl-b RING finger mutant mice revealed that both showed similarly enhanced FcvarepsilonRI signalling compared to wild-type cells for most parameters examined. A notable exception was a markedly higher level of activation of IkappaB kinase (IKK) in Cbl-b knockout BMMC compared to RING finger mutant-derived cells. In addition BMMCs from the Cbl-b RING finger mutant did not retard FcvarepsilonRI internalization to the extent observed for knockout cells. Most striking however was the finding that RING finger mutant mast cells do not produce the very high levels of TNF-alpha, IL-6, and MCP-1 evident in Cbl-b knockout cultures following FcvarepsilonRI activation. Thus the ability of Cbl-b to function as a negative regulator of FcvarepsilonRI signalling that promotes inflammatory cytokine production is largely independent of the RING finger domain.
Collapse
Affiliation(s)
- Morten P Oksvold
- School of Surgery and Pathology, University of Western Australia, Crawley, Western Australia 6009, Australia
| | | | | | | |
Collapse
|
136
|
Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon KD, Liang WS, Herbert RH, Beach T, Rohrer KC, Zhao AS, Leung D, Bryden L, Marlowe L, Kaleem M, Mastroeni D, Grover A, Heward CB, Ravid R, Rogers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Kukull W, Papassotiropoulos A, Stephan DA. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007; 54:713-20. [PMID: 17553421 PMCID: PMC2587162 DOI: 10.1016/j.neuron.2007.05.022] [Citation(s) in RCA: 334] [Impact Index Per Article: 19.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2007] [Revised: 05/15/2007] [Accepted: 05/20/2007] [Indexed: 11/28/2022]
Abstract
The apolipoprotein E (APOE) epsilon4 allele is the best established genetic risk factor for late-onset Alzheimer's disease (LOAD). We conducted genome-wide surveys of 502,627 single-nucleotide polymorphisms (SNPs) to characterize and confirm other LOAD susceptibility genes. In epsilon4 carriers from neuropathologically verified discovery, neuropathologically verified replication, and clinically characterized replication cohorts of 1411 cases and controls, LOAD was associated with six SNPs from the GRB-associated binding protein 2 (GAB2) gene and a common haplotype encompassing the entire GAB2 gene. SNP rs2373115 (p = 9 x 10(-11)) was associated with an odds ratio of 4.06 (confidence interval 2.81-14.69), which interacts with APOE epsilon4 to further modify risk. GAB2 was overexpressed in pathologically vulnerable neurons; the Gab2 protein was detected in neurons, tangle-bearing neurons, and dystrophic neuritis; and interference with GAB2 gene expression increased tau phosphorylation. Our findings suggest that GAB2 modifies LOAD risk in APOE epsilon4 carriers and influences Alzheimer's neuropathology.
Collapse
Affiliation(s)
- Eric M. Reiman
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Banner Alzheimer’s Institute, Phoenix, AZ 85006, USA
- Department of Psychiatry, University of Arizona, Tucson, AZ 85724, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
- *Correspondence: (E.M.R.), (D.A.S.)
| | - Jennifer A. Webster
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - Amanda J. Myers
- Department of Psychiatry and Behavioral Sciences, University of Miami, Miller School of Medicine, Miami, FL 33136, USA
- Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, 20892, USA
| | - John Hardy
- Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, 20892, USA
- Reta Lila Weston Laboratories, Department of Molecular Neuroscience, Institute of Neurology, Queen Square, London WC1N, 3BG, England
| | - Travis Dunckley
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - Victoria L. Zismann
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - Keta D. Joshipura
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - John V. Pearson
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - Diane Hu-Lince
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - Matthew J. Huentelman
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - David W. Craig
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - Keith D. Coon
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Division of Thoracic Oncology Research, St. Joseph’s Hospital, Phoenix, AZ 85013, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - Winnie S. Liang
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - RiLee H. Herbert
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - Thomas Beach
- Sun Health Research Institute, Sun City, AZ 85351, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - Kristen C. Rohrer
- Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, 20892, USA
| | - Alice S. Zhao
- Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, 20892, USA
| | - Doris Leung
- Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, 20892, USA
| | - Leslie Bryden
- Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, 20892, USA
| | - Lauren Marlowe
- Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, 20892, USA
| | - Mona Kaleem
- Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, 20892, USA
| | | | - Andrew Grover
- Sun Health Research Institute, Sun City, AZ 85351, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | | | - Rivka Ravid
- Netherlands Institute for Neurosciences, Dutch Royal Academy of Arts and Sciences, Meibergdreef 47 AB Amsterdam, The Netherlands
| | - Joseph Rogers
- Sun Health Research Institute, Sun City, AZ 85351, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - Michael L. Hutton
- Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
| | - Stacey Melquist
- Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
| | - Ron C. Petersen
- Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
| | - Gene E. Alexander
- Department of Psychology, Arizona State University, Tempe, AZ 85281, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - Richard J. Caselli
- Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
| | - Walter Kukull
- National Alzheimer’s Coordinating Center, Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA
| | - Andreas Papassotiropoulos
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Division of Molecular Psychology and Life Sciences Training Facility, Biozentrum, University of Basel, Switzerland
| | - Dietrich A. Stephan
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
- Banner Alzheimer’s Institute, Phoenix, AZ 85006, USA
- Arizona Alzheimer’s Consortium, Phoenix AZ 85006, USA
- *Correspondence: (E.M.R.), (D.A.S.)
| |
Collapse
|
137
|
Abstract
The Src family kinases Fyn and Lyn are important modulators of the molecular events initiated by engagement of the high-affinity IgE receptor (Fc epsilon RI). These kinases control many of the early signaling events and initiate the production of several lipid metabolites that have an important role in regulating mast cell responses. The intracellular level of phosphatidylinositol (3,4,5)-trisphosphate (PIP(3)), which is produced by phosphatidylinositol 3-OH kinase, plays an important role in determining the extent of a mast cells response to a stimulus. Enhanced levels lead to a hyperdegranulating phenotype (as seen in SHIP-1(-/-) and Lyn(-/-) mast cells), whereas decreased levels cause hypodegranulation (as seen in Fyn(-/-) mast cells). Downregulation of mast cell phosphatase and tensin homologue deleted on chromosone 10 expression, a phosphatase that reduces cellular levels of PIP(3), caused constitutive cytokine production, demonstrating that this response is particularly sensitive to PIP(3) levels. Lyn and Fyn are also intimately linked to other lipid kinases, like sphingosine kinases (SphK). By producing sphingosine-1-phosphate (S1P), SphKs contribute to mast cell chemotaxis and degranulation. In vivo studies now reveal that circulating S1P as well as that found within the mast cell is important in determining mast cell responsiveness. These studies demonstrate the connection between Src protein tyrosine kinases and lipid second messengers that control mast cell function and allergic responses.
Collapse
Affiliation(s)
- Juan Rivera
- Molecular Inflammation Section, Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892-1820, USA.
| | | |
Collapse
|
138
|
Abstract
The type I Fc epsilon receptor (Fc epsilon RI) is one of the better understood members of its class and is central to the immunological activation of mast cells and basophils, the key players in immunoglobulin E (IgE)-dependent immediate hypersensitivity. This review provides background information on several distinct regulatory mechanisms controlling this receptor's stimulus-response coupling network. First, we review the current understanding of this network's operation, and then we focus on the inhibitory regulatory mechanisms. In particular, we discuss the different known cytosolic molecules (e.g. kinases, phosphatases, and adapters) as well as cell membrane proteins involved in negatively regulating the Fc epsilon RI-induced secretory responses. Knowledge of this field is developing at a fast rate, as new proteins endowed with regulatory functions are still being discovered. Our understanding of the complex networks by which these proteins exert regulation is limited. Although the scope of this review does not include addressing several important biochemical and biophysical aspects of the regulatory mechanisms, it does provide general insights into a central field in immunology.
Collapse
Affiliation(s)
- Jakub Abramson
- Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
| | | |
Collapse
|
139
|
Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007; 7:365-78. [PMID: 17438574 DOI: 10.1038/nri2072] [Citation(s) in RCA: 428] [Impact Index Per Article: 25.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The high-affinity Fc receptor for IgE (FcepsilonRI), a multimeric immune receptor, is a crucial structure for IgE-mediated allergic reactions. In recent years, advances have been made in several important areas of the study of FcepsilonRI. The first area relates to FcepsilonRI-mediated biological responses that are antigen independent. The second area encompasses the biological relevance of the distinct signalling pathways that are activated by FcepsilonRI; and the third area relates to the accumulated evidence for the tight control of FcepsilonRI signalling through a broad array of inhibitory mechanisms, which are being developed into promising therapeutic approaches.
Collapse
Affiliation(s)
- Stefan Kraft
- Laboratory of Allergy and Immunology, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine 945, 71 Avenue Louis Pasteur, Boston, Massachusetts 02215, USA
| | | |
Collapse
|
140
|
Abstract
Store-operated calcium (SOC) entry is the major route of calcium influx in non-excitable cells, especially immune cells. The best characterized store-operated current, I(CRAC), is carried by calcium release activated calcium (CRAC) channels. The existence of the phenomenon of store-operated calcium influx was proposed almost two decades ago. However, in spite of rigorous research by many laboratories, the identity of the key molecules participating in the process has remained a mystery. In all these years, multiple different approaches have been adopted by countless researchers to identify the molecular players in this fundamental process. Along the way, many crucial discoveries have been made, some of which have been summarized here. The last couple of years have seen significant breakthroughs in the field-identification of STIM1 as the store Ca(2+) sensor and CRACM1 (Orai1) as the pore-forming subunit of the CRAC channel. The field is now actively engaged in deciphering the gating mechanism of CRAC channels. We summarize here the latest progress in this direction.
Collapse
Affiliation(s)
- Monika Vig
- Laboratory of Allergy and Immunology, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA 02215, USA
| | - Jean-Pierre Kinet
- Laboratory of Allergy and Immunology, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA 02215, USA
- Correspondence should be addressed to: Jean-Pierre Kinet, 617 667 1324 (phone), 617 667 1323 (fax),
| |
Collapse
|
141
|
Chan JHP, Liao W, Lau HYA, Wong WSF. Gab2 antisense oligonucleotide blocks rat basophilic leukemic cell functions. Int Immunopharmacol 2007; 7:937-44. [PMID: 17499196 DOI: 10.1016/j.intimp.2007.03.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2007] [Revised: 03/02/2007] [Accepted: 03/05/2007] [Indexed: 12/11/2022]
Abstract
Adapter molecule Grb2-associated binder-like protein 2 (Gab2) plays a critical role in FcepsilonRI-induced mast cell degranulation and activation. The present study aimed to investigate the pharmacological effects of an antisense oligonucleotide (ASO) targeted at Gab2 on the immune responses of rat basophilic leukemic (RBL)-2H3 cells. Gab2 ASOs were rationally designed and transfected into RBL-2H3 cells. Gab2 mRNA and protein knockdown was confirmed by real-time RT-PCR and immunoblotting, respectively. Effects of Gab2 ASO on FcepsilonRI-induced release of histamine and beta-hexosaminidase was measured by EIA and an enzymatic assay, respectively; signaling events by immunoblotting; and cytokine mRNA expression by RT-PCR. Effects of Gab2 ASO on cell adhesion and migration were performed on fibronectin-coated 96-well plate and transwells cell culture chambers, respectively. We have characterized a phosphorothioate-modified ASO targeted at Gab2 mRNA that was able to knockdown Gab2 mRNA and protein in RBL-2H3 cells. Gab2 ASO significantly blocked IgE-mediated mast cell release of beta-hexosaminidase and histamine; phosphorylation of Akt, p38 mitogen-activated protein kinase and PKCdelta; and up-regulation of cytokine mRNA levels (e.g. IL-4, -6, -9 and -13, and TNF-alpha). In addition, Gab2 ASO markedly prevented mast cell adhesion to fibronectin-coated plates and restrained random migration of RBL-2H3 cells in cell culture chambers. Our findings show that Gab2 knockdown in RBL-2H3 cells by ASO strategy can suppress many aspects of the mast cell functions and, therefore, a selective Gab2 ASO may have therapeutic potential for mast cell-dependent allergic disorders.
Collapse
MESH Headings
- Adaptor Proteins, Signal Transducing
- Animals
- Basophils/immunology
- Cell Adhesion/genetics
- Cell Movement/genetics
- Cytokines/genetics
- Cytokines/metabolism
- Fibronectins/metabolism
- Gene Targeting
- Histamine Release/genetics
- Histamine Release/immunology
- Leukemia, Basophilic, Acute/drug therapy
- Leukemia, Basophilic, Acute/immunology
- Mast Cells/immunology
- Oligonucleotides, Antisense/pharmacology
- Phosphoproteins/biosynthesis
- Phosphoproteins/genetics
- Phosphoproteins/metabolism
- Protein Serine-Threonine Kinases/metabolism
- RNA, Messenger/metabolism
- Rats
- Receptors, IgE/antagonists & inhibitors
- Receptors, IgE/genetics
- Signal Transduction/genetics
- Tumor Cells, Cultured
- beta-N-Acetylhexosaminidases/immunology
Collapse
Affiliation(s)
- Jasmine H P Chan
- Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | | | | | | |
Collapse
|
142
|
Abstract
PURPOSE OF REVIEW This review focuses on human and murine pathologies involving both osteoclasts and immune cells. These diseases have been relevant to the discovery of novel interactions and pathways shared between these two types of cells. RECENT FINDINGS Interactions between immune cells and osteoclasts were originally shown in murine models by gene targeting of molecules involved in the early steps of osteoclast differentiation, since receptor activator of nuclear factor kappa-B ligand (RANKL), RANK and TNFR-associated factor 6 knockout mice bore abnormalities of both bone resorption and immune system. Subsequently, osteoclast stimulation by RANKL secreted by lymphocytes in autoimmune diseases, such as rheumatoid arthritis, was found. More recently, the identification of immunoreceptor tyrosine-based activation motif receptors and adaptors important for both dendritic cells and osteoclast function has established a link between innate and adaptive immunity and bone. Finally, osteoclasts are also important for hematopoietic stem-cell mobilization, providing a further level of regulation of lymphoid cells. SUMMARY These findings open up a new field of research, osteoimmunology, which will unravel previously unsuspected links between bone remodelling and the immune response.
Collapse
Affiliation(s)
- Anna Villa
- Istituto Tecnologie Biomediche, CNR, Segrate, Italy.
| | | | | |
Collapse
|
143
|
Zhang Y, Diaz-Flores E, Li G, Wang Z, Kang Z, Haviernikova E, Rowe S, Qu CK, Tse W, Shannon KM, Bunting KD. Abnormal hematopoiesis in Gab2 mutant mice. Blood 2007; 110:116-24. [PMID: 17374739 PMCID: PMC1896106 DOI: 10.1182/blood-2006-11-060707] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Gab2 is an important adapter molecule for cytokine signaling. Despite its major role in signaling by receptors associated with hematopoiesis, the role of Gab2 in hematopoiesis has not been addressed. We report that despite normal numbers of peripheral blood cells, bone marrow cells, and c-Kit(+)Lin(-)Sca-1(+) (KLS) cells, Gab2-deficient hematopoietic cells are deficient in cytokine responsiveness. Significant reductions in the number of colony-forming units in culture (CFU-C) in the presence of limiting cytokine concentrations were observed, and these defects could be completely corrected by retroviral complementation. In earlier hematopoiesis, Gab2-deficient KLS cells isolated in vitro responded poorly to hematopoietic growth factors, resulting in an up to 11-fold reduction in response to a cocktail of stem cell factor, flt3 ligand, and thrombopoietin. Gab2-deficient c-Kit(+)Lin(-) cells also demonstrate impaired activation of extracellular signal-regulated kinase (ERK) and S6 in response to IL-3, which supports defects in activating the phosphatidylinositol-3 kinase (PI-3K) and mitogen-associated protein kinase (MAPK) signaling cascades. Associated with the early defects in cytokine response, competitive transplantation of Gab2(-/-) bone marrow cells resulted in defective long-term multilineage repopulation. Therefore, we demonstrate that Gab2 adapter function is intrinsically required for hematopoietic cell response to early-acting cytokines, resulting in defective hematopoiesis in Gab2-deficient mice.
Collapse
Affiliation(s)
- Yi Zhang
- Department of Medicine, Division of Hematology, Case Western Reserve University School of Medicine, Cleveland, OH 44106-7284, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
144
|
Kambayashi T, Koretzky GA. Proximal signaling events in FcɛRI-mediated mast cell activation. J Allergy Clin Immunol 2007; 119:544-52; quiz 553-4. [PMID: 17336609 DOI: 10.1016/j.jaci.2007.01.017] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2006] [Revised: 01/04/2007] [Accepted: 01/12/2007] [Indexed: 01/10/2023]
Abstract
Mast cells are central mediators of allergic diseases. Their involvement in allergic reactions is largely dependent on activation through the specific receptor for IgE (Fc epsilon RI). Cross-linking of Fc epsilon RI on mast cells initiates a cascade of signaling events that eventually results in degranulation, cytokine/chemokine production, and leukotriene release, contributing to allergic symptomology. Because of the importance of IgE in allergy, much focus has been placed on deciphering the signaling events that take place downstream of Fc epsilon RI. Studies have identified spleen tyrosine kinase as a key proximal regulator of Fc epsilon RI-mediated signaling. In this review, we discuss the multiple pathways that diverge from spleen tyrosine kinase with emphasis on the role of adapter molecules to orchestrate these signaling events. Understanding the molecular mechanisms underlying mast cell activation ideally will provide insights into the development of novel therapeutics to control allergic disease.
Collapse
Affiliation(s)
- Taku Kambayashi
- Department of Pathology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA
| | | |
Collapse
|
145
|
Frossi B, Rivera J, Hirsch E, Pucillo C. Selective Activation of Fyn/PI3K and p38 MAPK Regulates IL-4 Production in BMMC under Nontoxic Stress Condition. THE JOURNAL OF IMMUNOLOGY 2007; 178:2549-55. [PMID: 17277164 DOI: 10.4049/jimmunol.178.4.2549] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Mast cells have the ability to react to multiple stimuli, implicating these cells in many immune responses. Specific signals from the microenvironment in which mast cells reside can activate different molecular events that govern distinct mast cells responses. We previously demonstrated that hydrogen peroxide (H(2)O(2)) promotes IL-4 and IL-6 mRNA production and potentates FcepsilonRI-induced cytokine release in rat basophilic leukemia RBL-2H3 cells. To further evaluate the effect of an oxidative microenvironment (which is physiologically present in an inflammatory site) on mast cell function and the molecular events responsible for mast cell cytokine production in this environment, we analyzed the effect of H(2)O(2) treatment on IL-4 production in bone marrow-derived, cultured mast cells. Our findings show that nanomolar concentrations of H(2)O(2) induce cytokine secretion and enhance IL-4 production upon FcepsilonRI triggering. Oxidative stimulation activates a distinct signal transduction pathway that induces Fyn/PI3K/Akt activation and the selective phosphorylation of p38 MAP kinase. Moreover, H(2)O(2) induces AP-1 and NFAT complexes that recognize the IL-4 promoter. The absence of Fyn and PI3K or the inhibition of p38 MAPK activity demonstrated that they are essential for H(2)O(2)-driven IL-4 production. These findings show that mast cells can respond to an oxidative microenvironment by initiating specific signals capable of eliciting a selective response. The findings also demonstrate the dominance of the Fyn/p38 MAPK pathway in driving IL-4 production.
Collapse
Affiliation(s)
- Barbara Frossi
- Dipartimento di Scienze e Tecnologie Biomediche, Università di Udine, Udine, Italy
| | | | | | | |
Collapse
|
146
|
Tkaczyk C, Jensen BM, Iwaki S, Gilfillan AM. Adaptive and innate immune reactions regulating mast cell activation: from receptor-mediated signaling to responses. Immunol Allergy Clin North Am 2007; 26:427-50. [PMID: 16931287 DOI: 10.1016/j.iac.2006.05.011] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
In this article, we have described studies that have demonstrated that mast cells can be activated as a consequence of adaptive and innate immune reactions and that these responses can be modified by ligands for other receptors expressed on the surface of mast cells. These various stimuli differentially activate multiple signaling pathways within the mast cells required for the generation and/or release of inflammatory mediators. Thus, the composition of the suite of mediators released and the physiologic ramifications of these responses are dependent on the stimuli and the microenvironment in which the mast cells are activated. Knowledge of the different signaling molecules used by cell surface receptors may allow selective pharmacologic targeting such that inhibiting the adverse effects of mast cell activation can be achieved without influencing the beneficial effects of mast cell activation. The exact interconnections between the signaling pathways initiated by the surface receptors described in this article remain to be completely worked out; thus, this remains a topic for future investigation.
Collapse
Affiliation(s)
- Christine Tkaczyk
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11C206, 10 Center Drive, MSC 1881, Bethesda, MD 20892, USA
| | | | | | | |
Collapse
|
147
|
Abstract
The Tec family of tyrosine kinases consists of five members (Itk, Rlk, Tec, Btk, and Bmx) that are expressed predominantly in hematopoietic cells. The exceptions, Tec and Bmx, are also found in endothelial cells. Tec kinases constitute the second largest family of cytoplasmic protein tyrosine kinases. While B cells express Btk and Tec, and T cells express Itk, Rlk, and Tec, all four of these kinases (Btk, Itk, Rlk, and Tec) can be detected in mast cells. This chapter will focus on the biochemical and cell biological data that have been accumulated regarding Itk, Rlk, Btk, and Tec. In particular, distinctions between the different Tec kinase family members will be highlighted, with a goal of providing insight into the unique functions of each kinase. The known functions of Tec kinases in T cell and mast cell signaling will then be described, with a particular focus on T cell receptor and mast cell Fc epsilon RI signaling pathways.
Collapse
Affiliation(s)
- Martin Felices
- Department of Pathology, University of Massachusetts Medical School, Massachusetts, USA
| | | | | | | |
Collapse
|
148
|
Frigault MM, Naujokas MA, Park M. Gab2 requires membrane targeting and the met binding motif to promote lamellipodia, cell scatter, and epithelial morphogenesis downstream from the met receptor. J Cell Physiol 2007; 214:694-705. [PMID: 17894413 DOI: 10.1002/jcp.21264] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Gab1 and Gab2 are conserved scaffolding proteins that amplify and integrate signals stimulated by many growth factor receptors including the Met receptor. Gab1 acts to diversify the signal downstream from Met through the recruitment of multiple signaling proteins, and is essential for epithelial morphogenesis. However, whereas Gab1 and Gab2 are both expressed in epithelial cells, Gab2 fails to support a morphogenic response. We demonstrate that Gab1 and Gab2 are divergent in their function whereby Gab1, but not Gab2, promotes lamellipodia formation, and is localized to the membrane of lamellipodia upon Met activation. We have identified activation of ERK1/2 as a requirement for lamellipodia formation. Moreover, activated ERK1/2 are localized to lamellipodia in Gab1 expressing cells but not in cells that overexpress Gab2. By structure-function studies, we identify that enhanced membrane localization conferred through the addition of a myristoylation signal, together with the addition of the direct Met binding motif (MBM) from Gab1, are required to promote lamellipodia and confer a morphogenic signaling response to Gab2. Moreover, the morphogenesis competent myristoylated Gab2MBM promotes localization of activated ERK1/2 to the leading edge of lamellipodia in a similar manner to Gab1. Hence, subcellular localization of the Gab scaffold, as well as the ability of Gab to interact directly with the Met receptor, are both essential components of the morphogenic signaling response which involves lamellipodia formation and the localization of ERK1/2 activation in membrane ruffles.
Collapse
Affiliation(s)
- Melanie M Frigault
- Department of Biochemistry, Molecular Oncology Group, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
| | | | | |
Collapse
|
149
|
Itoh S, Yoshitake F, Narita H, Ishihara K, Ebisu S. Gab2 plays distinct roles in bone homeostasis at different time points. J Bone Miner Metab 2007; 25:81-5. [PMID: 17323176 DOI: 10.1007/s00774-006-0731-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2006] [Accepted: 10/31/2006] [Indexed: 10/23/2022]
Abstract
Grb2-associated binder 2 (Gab2) is an adaptor molecule that can be tyrosine phosphorylated by various growth factors and cytokines. Gab2 is known to play a role in signaling pathways downstream of cytokines that regulate bone homeostasis, including M-CSF, RANKL, and IL-6. To clarify the role of Gab2 in bone homeostasis during distinct phases of skeletal development, we compared phenotypic changes in bone homeostasis in Gab2(-/-) mice at two different ages. Although Gab2(-/-) mice showed increased bone volume at both time points, the reasons underlying the increased bone volume differed. At 6 weeks, the increased bone volume was due to enhanced bone resorption and bone formation, indicating that Gab2 plays a negative regulatory role for both osteoclastogenesis and osteoblast differentiation. At 12 weeks, the increased bone volume resulted from reduced osteoclast differentiation, indicating that Gab2 plays a positive regulatory role for osteoclastogenesis. Thus, Gab2 plays opposite roles in osteoclastogenesis during the phases of skeletal development and maintenance.
Collapse
Affiliation(s)
- Shousaku Itoh
- Department of Restorative Dentistry and Endodontology, Osaka University Graduate School of Dentistry, 1-8 Yamada-oka, Suita, Osaka 565-0871, Japan.
| | | | | | | | | |
Collapse
|
150
|
Liu Y, Zhu M, Nishida K, Hirano T, Zhang W. An essential role for RasGRP1 in mast cell function and IgE-mediated allergic response. ACTA ACUST UNITED AC 2006; 204:93-103. [PMID: 17190838 PMCID: PMC2118421 DOI: 10.1084/jem.20061598] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Cross-linking of the FcepsilonRI activates the phosphatidyl inositol 3 kinase (PI3K) and mitogen-activated protein kinase pathways. Previous studies demonstrate that Ras guanyl nucleotide-releasing protein (RasGRP)1 is essential in T cell receptor-mediated Ras-Erk activation. Here, we report that RasGRP1 plays an important role in FcepsilonRI-mediated PI3K activation and mast cell function. RasGRP1-deficient mice failed to mount anaphylactic allergic reactions. RasGRP1-/- mast cells had markedly reduced degranulation and cytokine production. Although FcepsilonRI-mediated Erk activation was normal, PI3K activation was diminished. Consequently, activation of Akt, PIP3-dependent kinase, and protein kinase C delta was defective. Expression of a constitutively active form of N-Ras could rescue the degranulation defect and Akt activation. We further demonstrated that RasGRP1-/- mast cells were defective in granule translocation, microtubule formation, and RhoA activation. Our results identified RasGRP1 as an essential regulator of mast cell function.
Collapse
Affiliation(s)
- Yan Liu
- Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA
| | | | | | | | | |
Collapse
|